Share Price and Basic Stock Data
Last Updated: February 13, 2026, 9:51 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
ANG Lifesciences India Ltd operates in the pharmaceuticals industry, with a market capitalization of ₹34.3 Cr and a current share price of ₹26.2. The company has experienced fluctuating revenue trends over the past few years, with sales recorded at ₹206.82 Cr for the fiscal year ending March 2023, a decline from ₹348.52 Cr in March 2022. The trailing twelve months (TTM) sales stood at ₹92.08 Cr, indicating a continued downward trajectory. Quarterly sales figures also reflect this trend, with the latest reported revenue of ₹29.58 Cr for September 2023, significantly lower than previous quarters. The company’s operational struggles are evident, as it reported a drop in sales from ₹58.39 Cr in September 2022 to ₹29.58 Cr in September 2023. This decline raises concerns about the company’s market position and ability to generate consistent revenue in a competitive environment.
Profitability and Efficiency Metrics
Profitability metrics for ANG Lifesciences indicate significant challenges, as the company reported a net profit of ₹-0.66 Cr in March 2023, which further declined to ₹-10.34 Cr by March 2025. The operating profit margin (OPM) registered a low of 8.55% in the latest quarter, reflecting tight cost controls but insufficient revenue generation. Furthermore, the interest coverage ratio (ICR) stood at -0.02x, signaling severe difficulties in meeting interest obligations. The return on equity (ROE) was reported at 13.8%, but this figure masks the underlying profitability issues highlighted by consistent net losses. The cash conversion cycle increased to 158.34 days, indicating inefficiencies in working capital management. Overall, these profitability and efficiency metrics underscore the need for ANG Lifesciences to implement strategic changes to restore financial health and improve operational performance.
Balance Sheet Strength and Financial Ratios
ANG Lifesciences’ balance sheet reveals a concerning leverage situation, with total borrowings amounting to ₹78.12 Cr against reserves of ₹52.20 Cr. The debt-to-equity ratio stood at 1.26x, suggesting a high reliance on debt financing, which is a risk factor in the current economic climate. The book value per share decreased from ₹66.02 in March 2023 to ₹48.99 in March 2025, indicating erosion of shareholder value. Furthermore, the company recorded a negative return on capital employed (ROCE) of -3.54% in March 2025, highlighting inefficiencies in utilizing capital effectively. Despite these challenges, the current ratio remains at a manageable 1.15x, suggesting that the company can meet its short-term obligations. However, the overall financial ratios depict a company in distress, with the need for significant restructuring to enhance balance sheet strength.
Shareholding Pattern and Investor Confidence
The shareholding pattern of ANG Lifesciences indicates a strong commitment from promoters, who hold 70.60% of the total shares as of March 2025. This level of promoter ownership can often instill confidence among retail investors, but the declining number of shareholders—from 7,163 in March 2023 to 6,273 by September 2025—raises concerns about investor sentiment. The public shareholding remains at 29.40%, suggesting limited diversification of ownership. The absence of Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) further reflects a lack of confidence from larger institutional players. This concentrated ownership, coupled with the company’s financial struggles, may deter new investments and hinder the stock’s recovery. Therefore, ANG Lifesciences must work to regain investor trust through improved financial performance and transparency.
Outlook, Risks, and Final Insight
Looking ahead, ANG Lifesciences faces a challenging road to recovery, with several risks and opportunities. The primary risks include high debt levels, ongoing operational inefficiencies, and a declining revenue trend, which could hinder the company’s ability to attract new investments or sustain its current operations. On the other hand, potential strengths lie in its established market presence and the commitment of its promoters, which could serve as a foundation for future recovery. For a turnaround, the company must focus on improving operational efficiencies and exploring new revenue streams. If ANG Lifesciences can successfully implement strategic changes, it may stabilize its financial performance and regain investor confidence. However, without decisive action, the risks of continued losses and shareholder erosion remain significant.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 129 Cr. | 103 | 143/84.3 | 26.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.15/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,391 Cr. | 312 | 479/192 | 71.0 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 28.3 Cr. | 38.2 | 79.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 84.4 Cr. | 57.6 | 57.6/17.0 | 201 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,957.38 Cr | 1,098.00 | 53.12 | 201.93 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 58.39 | 45.17 | 31.88 | 50.61 | 29.58 | 17.10 | 34.08 | 16.18 | 32.16 | 23.91 | 17.67 | 24.53 | 25.97 |
| Expenses | 49.15 | 43.03 | 43.48 | 44.94 | 28.26 | 18.82 | 30.23 | 18.11 | 29.70 | 25.89 | 18.03 | 22.67 | 23.75 |
| Operating Profit | 9.24 | 2.14 | -11.60 | 5.67 | 1.32 | -1.72 | 3.85 | -1.93 | 2.46 | -1.98 | -0.36 | 1.86 | 2.22 |
| OPM % | 15.82% | 4.74% | -36.39% | 11.20% | 4.46% | -10.06% | 11.30% | -11.93% | 7.65% | -8.28% | -2.04% | 7.58% | 8.55% |
| Other Income | 0.20 | 0.32 | 9.20 | 0.34 | 0.33 | -0.09 | -1.49 | 1.36 | 0.36 | -0.03 | 0.75 | 0.17 | 0.21 |
| Interest | 3.20 | 2.84 | 1.11 | 1.94 | 1.96 | 1.99 | 3.44 | 1.67 | 1.87 | 1.71 | 2.05 | 1.61 | 1.59 |
| Depreciation | 1.90 | 1.92 | 2.82 | 1.94 | 1.97 | 2.02 | 1.83 | 1.51 | 1.62 | 1.84 | 1.30 | 1.45 | 1.45 |
| Profit before tax | 4.34 | -2.30 | -6.33 | 2.13 | -2.28 | -5.82 | -2.91 | -3.75 | -0.67 | -5.56 | -2.96 | -1.03 | -0.61 |
| Tax % | 39.63% | -30.43% | -20.54% | 25.35% | -10.09% | -20.96% | 23.71% | -26.13% | 61.19% | -17.99% | -34.46% | -23.30% | 29.51% |
| Net Profit | 2.62 | -1.60 | -5.03 | 1.60 | -2.05 | -4.59 | -3.60 | -2.77 | -1.07 | -4.57 | -1.94 | -0.79 | -0.80 |
| EPS in Rs | 2.02 | -1.23 | -3.85 | 1.23 | -1.57 | -3.52 | -2.76 | -2.12 | -0.82 | -3.50 | -1.49 | -0.60 | -0.61 |
Last Updated: December 28, 2025, 4:29 am
Below is a detailed analysis of the quarterly data for ANG Lifesciences India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 25.97 Cr.. The value appears strong and on an upward trend. It has increased from 24.53 Cr. (Jun 2025) to 25.97 Cr., marking an increase of 1.44 Cr..
- For Expenses, as of Sep 2025, the value is 23.75 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 22.67 Cr. (Jun 2025) to 23.75 Cr., marking an increase of 1.08 Cr..
- For Operating Profit, as of Sep 2025, the value is 2.22 Cr.. The value appears strong and on an upward trend. It has increased from 1.86 Cr. (Jun 2025) to 2.22 Cr., marking an increase of 0.36 Cr..
- For OPM %, as of Sep 2025, the value is 8.55%. The value appears strong and on an upward trend. It has increased from 7.58% (Jun 2025) to 8.55%, marking an increase of 0.97%.
- For Other Income, as of Sep 2025, the value is 0.21 Cr.. The value appears strong and on an upward trend. It has increased from 0.17 Cr. (Jun 2025) to 0.21 Cr., marking an increase of 0.04 Cr..
- For Interest, as of Sep 2025, the value is 1.59 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.61 Cr. (Jun 2025) to 1.59 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Sep 2025, the value is 1.45 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.45 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.61 Cr.. The value appears strong and on an upward trend. It has increased from -1.03 Cr. (Jun 2025) to -0.61 Cr., marking an increase of 0.42 Cr..
- For Tax %, as of Sep 2025, the value is 29.51%. The value appears to be increasing, which may not be favorable. It has increased from -23.30% (Jun 2025) to 29.51%, marking an increase of 52.81%.
- For Net Profit, as of Sep 2025, the value is -0.80 Cr.. The value appears to be declining and may need further review. It has decreased from -0.79 Cr. (Jun 2025) to -0.80 Cr., marking a decrease of 0.01 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.61. The value appears to be declining and may need further review. It has decreased from -0.60 (Jun 2025) to -0.61, marking a decrease of 0.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:14 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 34.50 | 36.84 | 54.92 | 66.93 | 75.13 | 121.27 | 126.08 | 154.24 | 348.52 | 206.82 | 131.30 | 89.73 | 92.08 |
| Expenses | 29.61 | 33.72 | 50.19 | 60.43 | 67.83 | 109.63 | 113.65 | 138.91 | 282.98 | 195.15 | 121.75 | 90.75 | 90.34 |
| Operating Profit | 4.89 | 3.12 | 4.73 | 6.50 | 7.30 | 11.64 | 12.43 | 15.33 | 65.54 | 11.67 | 9.55 | -1.02 | 1.74 |
| OPM % | 14.17% | 8.47% | 8.61% | 9.71% | 9.72% | 9.60% | 9.86% | 9.94% | 18.81% | 5.64% | 7.27% | -1.14% | 1.89% |
| Other Income | 0.12 | 0.09 | 0.21 | 0.25 | 0.69 | 0.23 | 0.42 | 0.75 | 0.95 | 9.84 | -0.89 | 1.99 | 1.10 |
| Interest | 1.51 | 1.66 | 1.66 | 1.77 | 1.85 | 2.64 | 3.22 | 3.98 | 8.31 | 10.92 | 9.77 | 7.64 | 6.96 |
| Depreciation | 3.05 | 0.95 | 1.06 | 1.17 | 1.19 | 1.12 | 1.23 | 2.24 | 5.12 | 8.52 | 7.75 | 6.27 | 6.04 |
| Profit before tax | 0.45 | 0.60 | 2.22 | 3.81 | 4.95 | 8.11 | 8.40 | 9.86 | 53.06 | 2.07 | -8.86 | -12.94 | -10.16 |
| Tax % | 55.56% | 31.67% | 25.23% | 25.98% | 24.65% | 30.33% | 27.50% | 26.47% | 25.18% | 131.88% | -2.48% | -20.02% | |
| Net Profit | 0.19 | 0.40 | 1.65 | 2.82 | 3.72 | 5.65 | 6.10 | 7.25 | 39.71 | -0.66 | -8.65 | -10.34 | -8.10 |
| EPS in Rs | 0.21 | 0.43 | 1.79 | 3.07 | 2.86 | 4.35 | 4.69 | 5.58 | 30.55 | -0.51 | -6.62 | -7.92 | -6.20 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.61% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 110.53% | 312.50% | 70.91% | 31.91% | 51.88% | 7.96% | 18.85% | 447.72% | -101.66% | -1210.61% | -19.54% |
| Change in YoY Net Profit Growth (%) | 0.00% | 201.97% | -241.59% | -38.99% | 19.97% | -43.92% | 10.89% | 428.87% | -549.39% | -1108.94% | 1191.07% |
ANG Lifesciences India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -7% |
| 3 Years: | -36% |
| TTM: | 1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | -45% |
| 1 Year: | -48% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | -8% |
| Last Year: | -14% |
Last Updated: September 5, 2025, 2:16 pm
Balance Sheet
Last Updated: December 10, 2025, 3:48 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.68 | 3.68 | 3.68 | 3.68 | 5.18 | 5.18 | 5.18 | 5.18 | 10.37 | 13.06 | 13.06 | 13.06 | 13.06 |
| Reserves | -0.97 | -0.57 | 1.09 | 3.81 | 17.99 | 23.58 | 29.37 | 36.17 | 73.11 | 72.48 | 64.01 | 53.75 | 52.20 |
| Borrowings | 11.03 | 10.15 | 11.77 | 14.01 | 17.42 | 21.90 | 20.83 | 42.40 | 60.99 | 55.56 | 59.36 | 70.58 | 78.12 |
| Other Liabilities | 11.44 | 12.59 | 18.95 | 25.34 | 27.57 | 30.24 | 38.69 | 58.49 | 124.21 | 111.40 | 81.00 | 71.28 | 80.68 |
| Total Liabilities | 25.18 | 25.85 | 35.49 | 46.84 | 68.16 | 80.90 | 94.07 | 142.24 | 268.68 | 252.50 | 217.43 | 208.67 | 224.06 |
| Fixed Assets | 9.04 | 8.78 | 9.02 | 8.90 | 9.47 | 20.60 | 20.94 | 21.89 | 82.32 | 78.68 | 53.35 | 52.63 | 49.79 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.07 | 11.57 | 0.16 | 0.23 | 0.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 3.52 | 3.52 | 3.52 | 3.52 | 3.52 |
| Other Assets | 16.12 | 17.05 | 26.45 | 37.85 | 47.10 | 60.12 | 72.88 | 119.93 | 182.84 | 170.30 | 160.56 | 152.52 | 170.75 |
| Total Assets | 25.18 | 25.85 | 35.49 | 46.84 | 68.16 | 80.90 | 94.07 | 142.24 | 268.68 | 252.50 | 217.43 | 208.67 | 224.06 |
Below is a detailed analysis of the balance sheet data for ANG Lifesciences India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.06 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.06 Cr..
- For Reserves, as of Sep 2025, the value is 52.20 Cr.. The value appears to be declining and may need further review. It has decreased from 53.75 Cr. (Mar 2025) to 52.20 Cr., marking a decrease of 1.55 Cr..
- For Borrowings, as of Sep 2025, the value is 78.12 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 70.58 Cr. (Mar 2025) to 78.12 Cr., marking an increase of 7.54 Cr..
- For Other Liabilities, as of Sep 2025, the value is 80.68 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 71.28 Cr. (Mar 2025) to 80.68 Cr., marking an increase of 9.40 Cr..
- For Total Liabilities, as of Sep 2025, the value is 224.06 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 208.67 Cr. (Mar 2025) to 224.06 Cr., marking an increase of 15.39 Cr..
- For Fixed Assets, as of Sep 2025, the value is 49.79 Cr.. The value appears to be declining and may need further review. It has decreased from 52.63 Cr. (Mar 2025) to 49.79 Cr., marking a decrease of 2.84 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 3.52 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.52 Cr..
- For Other Assets, as of Sep 2025, the value is 170.75 Cr.. The value appears strong and on an upward trend. It has increased from 152.52 Cr. (Mar 2025) to 170.75 Cr., marking an increase of 18.23 Cr..
- For Total Assets, as of Sep 2025, the value is 224.06 Cr.. The value appears strong and on an upward trend. It has increased from 208.67 Cr. (Mar 2025) to 224.06 Cr., marking an increase of 15.39 Cr..
However, the Borrowings (78.12 Cr.) are higher than the Reserves (52.20 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -6.14 | -7.03 | -7.04 | -7.51 | -10.12 | -10.26 | -8.40 | -27.07 | 4.55 | -43.89 | -49.81 | -71.60 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 79.67 | 62.22 | 108.86 | 139.39 | 156.19 | 125.66 | 133.34 | 139.10 | 103.67 | 137.85 | 192.56 | 264.24 |
| Inventory Days | 83.99 | 84.14 | 46.81 | 44.62 | 53.41 | 27.18 | 41.03 | 67.62 | 46.29 | 92.90 | 143.34 | 227.95 |
| Days Payable | 129.49 | 129.88 | 133.28 | 163.44 | 153.96 | 90.63 | 105.80 | 158.84 | 105.16 | 153.93 | 243.56 | 333.86 |
| Cash Conversion Cycle | 34.17 | 16.48 | 22.39 | 20.58 | 55.64 | 62.21 | 68.56 | 47.88 | 44.80 | 76.83 | 92.34 | 158.34 |
| Working Capital Days | 28.25 | 18.73 | 10.23 | 14.40 | 48.29 | 39.70 | 52.60 | 47.14 | 22.05 | 27.88 | 74.97 | 71.80 |
| ROCE % | 13.65% | 16.74% | 26.04% | 29.34% | 21.90% | 23.56% | 21.92% | 19.90% | 53.78% | 8.51% | 1.78% | -3.54% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -9.42 | -7.65 | 0.36 | 39.39 |
| Diluted EPS (Rs.) | -9.42 | -7.65 | 0.36 | 39.09 |
| Cash EPS (Rs.) | -4.33 | -1.36 | 6.96 | 44.56 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 48.99 | 58.41 | 66.02 | 80.81 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 48.99 | 58.41 | 66.02 | 80.81 |
| Revenue From Operations / Share (Rs.) | 71.10 | 111.89 | 168.39 | 341.77 |
| PBDIT / Share (Rs.) | -0.18 | 7.92 | 18.27 | 65.87 |
| PBIT / Share (Rs.) | -5.37 | 1.51 | 11.11 | 60.20 |
| PBT / Share (Rs.) | -12.03 | -8.20 | 2.01 | 51.61 |
| Net Profit / Share (Rs.) | -9.51 | -7.77 | -0.20 | 38.89 |
| NP After MI And SOA / Share (Rs.) | -9.51 | -7.77 | -0.20 | 38.89 |
| PBDIT Margin (%) | -0.26 | 7.07 | 10.84 | 19.27 |
| PBIT Margin (%) | -7.54 | 1.34 | 6.59 | 17.61 |
| PBT Margin (%) | -16.91 | -7.33 | 1.19 | 15.10 |
| Net Profit Margin (%) | -13.36 | -6.94 | -0.11 | 11.37 |
| NP After MI And SOA Margin (%) | -13.36 | -6.94 | -0.11 | 11.37 |
| Return on Networth / Equity (%) | -19.40 | -13.29 | -0.30 | 48.12 |
| Return on Capital Employeed (%) | -8.13 | 2.01 | 12.35 | 50.02 |
| Return On Assets (%) | -5.40 | -4.18 | -0.09 | 13.85 |
| Long Term Debt / Equity (X) | 0.29 | 0.18 | 0.23 | 0.25 |
| Total Debt / Equity (X) | 1.26 | 0.90 | 0.81 | 0.91 |
| Asset Turnover Ratio (%) | 0.39 | 0.55 | 0.77 | 0.00 |
| Current Ratio (X) | 1.15 | 1.24 | 1.15 | 1.16 |
| Quick Ratio (X) | 0.77 | 0.90 | 0.85 | 0.93 |
| Inventory Turnover Ratio (X) | 1.82 | 2.14 | 3.65 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 2.57 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 2.24 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 97.43 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 97.76 |
| Interest Coverage Ratio (X) | -0.02 | 0.94 | 2.01 | 7.67 |
| Interest Coverage Ratio (Post Tax) (X) | -0.42 | 0.23 | 0.97 | 5.53 |
| Enterprise Value (Cr.) | 106.47 | 122.38 | 163.11 | 313.54 |
| EV / Net Operating Revenue (X) | 1.15 | 0.83 | 0.74 | 0.88 |
| EV / EBITDA (X) | -429.30 | 11.83 | 6.84 | 4.59 |
| MarketCap / Net Operating Revenue (X) | 0.31 | 0.40 | 0.45 | 0.68 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 97.42 |
| Price / BV (X) | 0.46 | 0.77 | 1.15 | 2.90 |
| Price / Net Operating Revenue (X) | 0.31 | 0.40 | 0.45 | 0.68 |
| EarningsYield | -0.41 | -0.17 | 0.00 | 0.16 |
After reviewing the key financial ratios for ANG Lifesciences India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -9.42. This value is below the healthy minimum of 5. It has decreased from -7.65 (Mar 24) to -9.42, marking a decrease of 1.77.
- For Diluted EPS (Rs.), as of Mar 25, the value is -9.42. This value is below the healthy minimum of 5. It has decreased from -7.65 (Mar 24) to -9.42, marking a decrease of 1.77.
- For Cash EPS (Rs.), as of Mar 25, the value is -4.33. This value is below the healthy minimum of 3. It has decreased from -1.36 (Mar 24) to -4.33, marking a decrease of 2.97.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.99. It has decreased from 58.41 (Mar 24) to 48.99, marking a decrease of 9.42.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.99. It has decreased from 58.41 (Mar 24) to 48.99, marking a decrease of 9.42.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 71.10. It has decreased from 111.89 (Mar 24) to 71.10, marking a decrease of 40.79.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.18. This value is below the healthy minimum of 2. It has decreased from 7.92 (Mar 24) to -0.18, marking a decrease of 8.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is -5.37. This value is below the healthy minimum of 0. It has decreased from 1.51 (Mar 24) to -5.37, marking a decrease of 6.88.
- For PBT / Share (Rs.), as of Mar 25, the value is -12.03. This value is below the healthy minimum of 0. It has decreased from -8.20 (Mar 24) to -12.03, marking a decrease of 3.83.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -9.51. This value is below the healthy minimum of 2. It has decreased from -7.77 (Mar 24) to -9.51, marking a decrease of 1.74.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -9.51. This value is below the healthy minimum of 2. It has decreased from -7.77 (Mar 24) to -9.51, marking a decrease of 1.74.
- For PBDIT Margin (%), as of Mar 25, the value is -0.26. This value is below the healthy minimum of 10. It has decreased from 7.07 (Mar 24) to -0.26, marking a decrease of 7.33.
- For PBIT Margin (%), as of Mar 25, the value is -7.54. This value is below the healthy minimum of 10. It has decreased from 1.34 (Mar 24) to -7.54, marking a decrease of 8.88.
- For PBT Margin (%), as of Mar 25, the value is -16.91. This value is below the healthy minimum of 10. It has decreased from -7.33 (Mar 24) to -16.91, marking a decrease of 9.58.
- For Net Profit Margin (%), as of Mar 25, the value is -13.36. This value is below the healthy minimum of 5. It has decreased from -6.94 (Mar 24) to -13.36, marking a decrease of 6.42.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -13.36. This value is below the healthy minimum of 8. It has decreased from -6.94 (Mar 24) to -13.36, marking a decrease of 6.42.
- For Return on Networth / Equity (%), as of Mar 25, the value is -19.40. This value is below the healthy minimum of 15. It has decreased from -13.29 (Mar 24) to -19.40, marking a decrease of 6.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is -8.13. This value is below the healthy minimum of 10. It has decreased from 2.01 (Mar 24) to -8.13, marking a decrease of 10.14.
- For Return On Assets (%), as of Mar 25, the value is -5.40. This value is below the healthy minimum of 5. It has decreased from -4.18 (Mar 24) to -5.40, marking a decrease of 1.22.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from 0.18 (Mar 24) to 0.29, marking an increase of 0.11.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.26. This value exceeds the healthy maximum of 1. It has increased from 0.90 (Mar 24) to 1.26, marking an increase of 0.36.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.39. It has decreased from 0.55 (Mar 24) to 0.39, marking a decrease of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 1.15. This value is below the healthy minimum of 1.5. It has decreased from 1.24 (Mar 24) to 1.15, marking a decrease of 0.09.
- For Quick Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1. It has decreased from 0.90 (Mar 24) to 0.77, marking a decrease of 0.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.82. This value is below the healthy minimum of 4. It has decreased from 2.14 (Mar 24) to 1.82, marking a decrease of 0.32.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -0.02. This value is below the healthy minimum of 3. It has decreased from 0.94 (Mar 24) to -0.02, marking a decrease of 0.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -0.42. This value is below the healthy minimum of 3. It has decreased from 0.23 (Mar 24) to -0.42, marking a decrease of 0.65.
- For Enterprise Value (Cr.), as of Mar 25, the value is 106.47. It has decreased from 122.38 (Mar 24) to 106.47, marking a decrease of 15.91.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.15. This value is within the healthy range. It has increased from 0.83 (Mar 24) to 1.15, marking an increase of 0.32.
- For EV / EBITDA (X), as of Mar 25, the value is -429.30. This value is below the healthy minimum of 5. It has decreased from 11.83 (Mar 24) to -429.30, marking a decrease of 441.13.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.31, marking a decrease of 0.09.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has decreased from 0.77 (Mar 24) to 0.46, marking a decrease of 0.31.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.31, marking a decrease of 0.09.
- For EarningsYield, as of Mar 25, the value is -0.41. This value is below the healthy minimum of 5. It has decreased from -0.17 (Mar 24) to -0.41, marking a decrease of 0.24.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in ANG Lifesciences India Ltd:
- Net Profit Margin: -13.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -8.13% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -19.4% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.77
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 53.12)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.26
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -13.36%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Darbara Complex, Amritsar Punjab 143001 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajesh Gupta | Managing Director |
| Mrs. Saruchi Gupta | Whole Time Director |
| Mr. Rohit Mittal | Non Executive Director |
| Mrs. Chetna | Independent Director |
| Mr. Harvinder Singh | Independent Director |
| Mr. Sukhpal Singh | Independent Director |
FAQ
What is the intrinsic value of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd's intrinsic value (as of 14 February 2026) is ₹40.86 which is 57.15% higher the current market price of ₹26.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹34.0 Cr. market cap, FY2025-2026 high/low of ₹40.4/21.0, reserves of ₹52.20 Cr, and liabilities of ₹224.06 Cr.
What is the Market Cap of ANG Lifesciences India Ltd?
The Market Cap of ANG Lifesciences India Ltd is 34.0 Cr..
What is the current Stock Price of ANG Lifesciences India Ltd as on 14 February 2026?
The current stock price of ANG Lifesciences India Ltd as on 14 February 2026 is ₹26.0.
What is the High / Low of ANG Lifesciences India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of ANG Lifesciences India Ltd stocks is ₹40.4/21.0.
What is the Stock P/E of ANG Lifesciences India Ltd?
The Stock P/E of ANG Lifesciences India Ltd is .
What is the Book Value of ANG Lifesciences India Ltd?
The Book Value of ANG Lifesciences India Ltd is 50.0.
What is the Dividend Yield of ANG Lifesciences India Ltd?
The Dividend Yield of ANG Lifesciences India Ltd is 0.00 %.
What is the ROCE of ANG Lifesciences India Ltd?
The ROCE of ANG Lifesciences India Ltd is 3.54 %.
What is the ROE of ANG Lifesciences India Ltd?
The ROE of ANG Lifesciences India Ltd is 13.8 %.
What is the Face Value of ANG Lifesciences India Ltd?
The Face Value of ANG Lifesciences India Ltd is 10.0.